Literature DB >> 15832413

Effect of norcantharidin on proliferation and invasion of human gallbladder carcinoma GBC-SD cells.

Yue-Zu Fan1, Jin-Ye Fu, Ze-Ming Zhao, Cun-Qiu Chen.   

Abstract

AIM: To investigate the effect of norcantharidin on proliferation and invasion of human gallbladder carcinoma GBC-SD cells in vitro and its anticancer mechanism.
METHODS: Human gallbladder carcinoma GBC-SD cells were cultured by cell culture technique. The growth and the invasiveness of GBC-SD cells in vitro were evaluated by the tetrazolium-based colorimetric assay and by the Matrigel experiment and the crossing-river test. Expression of PCNA, Ki-67, MMP2 and TIMP2 proteins of GBC-SD cells was determined by streptavidin-biotin complex method.
RESULTS: In vitro norcantharidin inhibited the growth and proliferation of GBC-SD cells in a dose- and time-dependent manner, with the IC50 value of 56.18 microg/mL at 48 h. Norcantharidin began to inhibit the invasion of GBC-SD cells at the concentration of 5 microg/mL, and the invasive action of GBC-SD cells was inhibited completely and their crossing-river time was prolonged significantly at 40 microg/mL. After treatment with norcantharidin, the expression of PCNA, Ki-67, and MMP2 was significantly decreased. With the increase in TIMP2 expression, the MMP2 to TIMP2 ratio was decreased significantly (P<0.05).
CONCLUSION: Norcantharidin inhibits the proliferation and growth of human gallbladder carcinoma cells in vitro at relatively low concentrations by inhibiting PCNA and Ki-67 expression. Its anti-invasive activity may be the result of decrease in MMP2 to TIMP2 ratio and reduced cell motility.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15832413      PMCID: PMC4305630          DOI: 10.3748/wjg.v11.i16.2431

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  38 in total

1.  Potential new antitumor agents from an innovative combination of demethylcantharidin, a modified traditional Chinese medicine, with a platinum moiety.

Authors:  Y P Ho; K K To; S C Au-Yeung; X Wang; G Lin; X Han
Journal:  J Med Chem       Date:  2001-06-21       Impact factor: 7.446

Review 2.  Chemotherapy for gallbladder carcinoma--a surgeon's perspective.

Authors:  T Todoroki
Journal:  Hepatogastroenterology       Date:  2000 Jul-Aug

Review 3.  [Advances in the study of Cantharidin and its derivatives].

Authors:  Jian Liu; Jianhui Gao; Xiaoqiu Liu
Journal:  Zhong Yao Cai       Date:  2003-06

4.  Adjuvant external beam radiation therapy with concurrent chemotherapy in the management of gallbladder carcinoma.

Authors:  John J Kresl; Steven E Schild; George T Henning; Leonard L Gunderson; John Donohue; Henry Pitot; Michael G Haddock; David Nagorney
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-01-01       Impact factor: 7.038

5.  Inhibitory effect of norcantharidin on K562 human myeloid leukemia cells in vitro.

Authors:  S N Yi; J Wass; P Vincent; H Iland
Journal:  Leuk Res       Date:  1991       Impact factor: 3.156

6.  [The in vitro effect of norcantharidin on proliferation and invasion of human gallbladder carcinoma GBC-SD cells and its mechanism].

Authors:  Yue-zu Fan; Jin-ye Fu; Ze-ming Zhao; Chun-qiu Chen
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  2004-05

7.  Modified norcantharidins; synthesis, protein phosphatases 1 and 2A inhibition, and anticancer activity.

Authors:  Matthew E Hart; A Richard Chamberlin; Cecilia Walkom; Jennette A Sakoff; Adam McCluskey
Journal:  Bioorg Med Chem Lett       Date:  2004-04-19       Impact factor: 2.823

8.  Effector mechanisms of norcantharidin-induced mitotic arrest and apoptosis in human hepatoma cells.

Authors:  Yan-Nian Chen; Jung-Chou Chen; Sui-Chu Yin; Guang-Sheng Wang; Wei Tsauer; Sheng-Feng Hsu; Shih-Lan Hsu
Journal:  Int J Cancer       Date:  2002-07-10       Impact factor: 7.396

9.  Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies.

Authors:  William R Jarnagin; Leyo Ruo; Sarah A Little; David Klimstra; Michael D'Angelica; Ronald P DeMatteo; Raquel Wagman; Leslie H Blumgart; Yuman Fong
Journal:  Cancer       Date:  2003-10-15       Impact factor: 6.860

Review 10.  Medical uses of mylabris in ancient China and recent studies.

Authors:  G S Wang
Journal:  J Ethnopharmacol       Date:  1989-09       Impact factor: 4.360

View more
  11 in total

1.  Pachymic acid inhibits tumorigenesis in gallbladder carcinoma cells.

Authors:  Yueguang Chen; Peilong Lian; Yanfeng Liu; Kesen Xu
Journal:  Int J Clin Exp Med       Date:  2015-10-15

2.  Down-regulation of FoxM1 inhibits viability and invasion of gallbladder carcinoma cells, partially dependent on inducement of cellular senescence.

Authors:  Jie Tao; Xin-Sen Xu; Yan-Zhou Song; Kai Qu; Qi-Fei Wu; Rui-Tao Wang; Fan-Di Meng; Ji-Chao Wei; Shun-Bin Dong; Yue-Lang Zhang; Min-Hui Tai; Ya-Feng Dong; Lin Wang; Chang Liu
Journal:  World J Gastroenterol       Date:  2014-07-28       Impact factor: 5.742

Review 3.  Antitumor potential of the protein phosphatase inhibitor, cantharidin, and selected derivatives.

Authors:  Yulin Ren; A Douglas Kinghorn
Journal:  Bioorg Med Chem       Date:  2021-01-09       Impact factor: 3.641

Review 4.  Norcantharidin, derivative of cantharidin, for cancer stem cells.

Authors:  Chen-Hsi Hsieh; K S Clifford Chao; Hui-Fen Liao; Yu-Jen Chen
Journal:  Evid Based Complement Alternat Med       Date:  2013-09-02       Impact factor: 2.629

5.  Isolation of a human gallbladder cancer cell clone with high invasive phenotype in vitro and metastatic potential in orthotopic model and inhibition of its invasiveness by heparanase antisense oligodeoxynucleotides.

Authors:  Xin-Zhong Chang; Zhan-Min Wang; Jin-Ming Yu; Fu-Guo Tian; Wei Jin; Yi Zhang; Jie Yu; Lian-Fang Li; Xiao-Feng Liu; Zhi-Wei Li; Zhi-Min Shao
Journal:  Clin Exp Metastasis       Date:  2007-01-27       Impact factor: 4.510

6.  Norcantharidin Induces HL-60 Cells Apoptosis In Vitro.

Authors:  You-Ming Jiang; Zhen-Zhi Meng; Guang-Xin Yue; Jia-Xu Chen
Journal:  Evid Based Complement Alternat Med       Date:  2012-06-24       Impact factor: 2.629

7.  A potential small-molecule synthetic antilymphangiogenic agent norcantharidin inhibits tumor growth and lymphangiogenesis of human colonic adenocarcinomas through blocking VEGF-A,-C,-D/VEGFR-2,-3 "multi-points priming" mechanisms in vitro and in vivo.

Authors:  Xin-Ping Li; Wei Jing; Jian-Jun Sun; Zhong-Yan Liu; Jing-Tao Zhang; Wei Sun; Wei Zhu; Yue-Zu Fan
Journal:  BMC Cancer       Date:  2015-07-19       Impact factor: 4.430

8.  N-Farnesyloxy-norcantharimide inhibits progression of human leukemic Jurkat T cells through regulation of mitogen-activated protein kinase and interleukin-2 production.

Authors:  Ming-Che Chang; Jin-Yi Wu; Hui-Fen Liao; Yu-Jen Chen; Cheng-Deng Kuo
Journal:  Anticancer Drugs       Date:  2015-11       Impact factor: 2.248

9.  Inhibition of tumor vasculogenic mimicry and prolongation of host survival in highly aggressive gallbladder cancers by norcantharidin via blocking the ephrin type a receptor 2/focal adhesion kinase/paxillin signaling pathway.

Authors:  Hui Wang; Wei Sun; Wen-Zhong Zhang; Chun-Yan Ge; Jing-Tao Zhang; Zhong-Yan Liu; Yue-Zu Fan
Journal:  PLoS One       Date:  2014-05-08       Impact factor: 3.240

10.  Comparative assessment of therapeutic safety of norcantharidin, N-farnesyloxy-norcantharimide, and N-farnesyl-norcantharimide against Jurkat T cells relative to human normal lymphoblast: A quantitative pilot study.

Authors:  Ming-Che Chang; Jin-Yi Wu; Hui-Fen Liao; Yu-Jen Chen; Cheng-Deng Kuo
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.